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Abstract
Background: In the past few years there has been a political imperative driving the creation of European Reference
Networks as these are considered a promising way to achieve equity in access to the most up to date medical care
across Europe. The right to equity in the access to care was established by the directive of the European Parliament
and of the Council on the application of patients' rights in cross-border healthcare. The particular situation for Rare
Diseases whereby sharing of expertise can be regarded as especially valuable, as well as the work that is already in
place in the networking of Rare Diseases experts means that Rare Diseases are considered excellent models for the
development of European Reference Networks.
Discussion: To be effective, a Rare Disease network should be based on the common effort of different stakeholders
and be built on what is present in the community. European Reference Networks are an excellent model to overcome
some of the specificities of rare diseases: scarcity of patients, resources and expertise. European Reference Networks
with broad scope will allow the rare disease community the possibility of reaching a larger number of patients and
more diversified rare diseases. The practical value of grouping rare diseases in broad networks is well demonstrated in
different grouping systems present in Europe (EURORDIS grouping of diseases, “Les filières de santé maladies rares”,
Orphanet classification and the UK Research Model).
Summary: In this paper the authors, partners of EUCERD Joint Action, address some of the questions that surround
the establishment of European Reference Networks. We will focus on how Rare Diseases could be efficiently grouped
in order to constitute European Reference Networks and how they might be structured to allow each and every
disease to benefit from networking.
Keywords: Rare Diseases, European policies, European reference networks, Grouping of rare diseases
Background
Rare diseases (RD) are defined in the European Union
as life-threatening or chronically debilitating conditions
that affect less than 5 per 10 000 people. It has been
well established in the academic and patient literature
that the small number of patients and the geographic
dispersion is an obstacle to the diagnosis, access to
care, research and improvement of medical expertise.
For a number of years it has been advocated that
linking experts and pooling resources through networks
would enable to overcome these obstacles, and signifi-
cant expertise in networking across different RD groups
has been established as demonstrated by the Orphanet
Report: Series on Research Infrastructures for Rare
Diseases in Europe (http://www.orpha.net/orphacom/
cahiers/docs/GB/Research_Infrastructures_for_rare_dis-
eases_in_Europe.pdf ).
The European Union has tried to combat the lack of
specific health policies for rare diseases in the different
Member States, through the establishment of an overall
strategy for Member States to support the equity in
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access to prevention, diagnosis and care for patients with
a RD throughout the European Union.
In March 2011 the European Directive on the appli-
cation of patient’s rights in cross-border healthcare
[1] was adopted and established a legal framework for
cross-border healthcare within the European Union
(EU). The directive clarifies the rules of access to
healthcare in a EU country different from the country
of origin of the patient. It also clarifies the rules of
reimbursement. One of the aims of the directive is to
promote cooperation between the health systems of
Member States including the establishment of European
Reference Networks (ERNs). A network is by definition an
association of individuals sharing common interests and
providing mutual support and information. Due to its
nature networks have the potential to cover large ter-
ritorial areas. When we transpose these definitions to
the organization of medical care, ERNs are an excel-
lent model to overcome some of the specific prob-
lems of rare diseases: scarcity of patients, resources
and expertise.
The recent publication of Implementing and Delegated
Acts by the European Commission (EC) provides a
framework for the creation of ERNs [2, 3]. Although RD
are well placed to benefit from these instruments, it
should be emphasised that ERNs were not specifically
conceived for RD. It is also of note that the themes to be
covered by ERNs are not prescribed in these acts.
In 2013 a study of the European Observatory on
Health Systems and Policies [4] proposed some funda-
mental questions that should be tackled in the develop-
ment of reference networks: which medical conditions
or interventions should be addressed; what are the
drivers and motivations for their creation; which regula-
tory, administrative and financial procedures are needed;
and finally what are the impact and challenges for devel-
oping ERNs at European level.
The EUCERD Joint Action (EJA) is, since March 2012,
assisting the EC with the formulation and implementa-
tion of its activities in the field of RD. Meantime, exten-
sive work has been carried out by the EJA partners
(John Walton Muscular Dystrophy Research Centre at
Newcastle University and the European Organisation for
Rare Diseases (EURORDIS)) with the European Union
Committee of Experts in Rare Diseases/Commission
Expert Group on Rare Diseases (EUCERD/CEGRD) on
the generation of recommendations for RD ERNs. An im-
portant aspect with such a heterogeneous group of dis-
eases as “rare diseases” is how to group them adequately
to allow efficient and equitable functioning of RD ERNs.
In this paper we have focused on the process by which
a decision was reached and adopted by the CEGRD as to
how we could efficiently group RD in order to support
the constitution of well-functioning ERNs.
Discussion
Healthcare networks
A significant body of work has been conducted around
RD ERNs and the likely benefits have been well docu-
mented [1, 5–7]. ERNs for RD can be established con-
sidering different aspects, such as: disease frequency
and prevalence, cost-effectiveness, or the need to reach
sufficient numbers of patients to increase expertise and
deliver the best quality of care. However, independently
of the established priority, a RD ERN to be effective
should be based on the common effort of different
stakeholders and build on what is already present in the
community. The principles for the establishment of RD
ERNs were enshrined in the EUCERD recommenda-
tions on this topic in January 2013 [8].
The concept behind the implementation of ERNs as a
model for healthcare provision has clearly evolved from
the pure aim to improve cost-effectiveness to encompass
improving quality of care and equity in access to health-
care. This shift makes it relevant to consider that the
priority around RD ERNs should be reaching sufficient
numbers of patients to increase expertise and deliver the
best quality of care. Therefore, one of the main chal-
lenges for the society in general and for the rare diseases
stakeholders in particular is to determine how ERNs
should be organized i.e. how many should be created
and how should different diseases be grouped in order
to achieve the above-mentioned priority.
Why organize ERNs around groups of diseases?
A network, in social sciences, is defined as an associ-
ation of individuals sharing common interests and pro-
viding mutual support and information [9]. Networks
have the potential to achieve a large coverage depending
on the number of members involved. When we trans-
pose these definitions to the organization of medical
care, ERNs are an excellent model to overcome some of
the specific problems of rare diseases: scarcity of pa-
tients, resources and expertise. ERNs with a broad scope
will allow the rare disease community the possibility of
reaching a larger number of patients and a more diverse
range of rare diseases.
With respect to existing networks, ERN status will
need to represent a clear added-value such as: easier
adoption and spread of innovations in medical science
and health technologies; facilitation of medical training;
faster dissemination of agreed standards of care and
general knowledge in the area of expertise; and in-
creased profile and recognition of the participants.
ERNs will attract the best experts and more patients
and although they are supposed to facilitate cross-
border health care it is expected that the pooling of re-
sources and the e-Health solutions will decrease the
burden of travelling for the patients. Another expected
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though not explicit benefit is that the Networks and
their members will be in a better position to apply for
research funding and further develop and accelerate
basic and translational research.
Existing networks in the RD field have arisen “ad hoc”
in response to specific funding calls either from DG
Sanco (now Santé) or from DG research. The diseases
covered by these networks are often of low/very low
prevalence and the networks highly focussed. The aims
of the networks are highly variable and their sustainabil-
ity has been a major issue (Table 1). No mechanism has
yet been in place to ensure that all or even a majority of
RD patients might have access to a network for their
particular disease. In the process of drafting and adopt-
ing the EUCERD recommendations on RD ERNs, this
issue of inclusivity was debated in some detail. Patients’
organisations such as EURORDIS strongly advocated
that ERNs should be inclusive and should not be created
for every single RD, on the grounds that this would leave
many patients without an ‘umbrella’ ERN [10]. Creating
6–8000 individual ERNs (as many as the estimated num-
ber of rare diseases) would be impossible, and not desir-
able from a clinical perspective.
Following the publication of the delegating and imple-
menting acts, further discussion within the CEGRD indi-
cated that more guidance was needed on the grouping
of diseases into ‘families’ that can be addressed by
comprehensive ERNs as a realistic and constructive
approach.
Grouping exercise
In order to be successful, ERNs need to take into con-
sideration existing national practices and networking
systems which entails both opportunities and chal-
lenges. Existing networks and national healthcare au-
thorities need to be made aware of the economical,
scientific and patient care benefits of joint versus single
disease networks.
The EUCERD Recommendations on Rare Diseases
European Reference Networks (RD ERNS), published
on 31 January 2013, aimed at provide guidance to the
Member States and the EC on the criteria needed to
be fulfilled to establish RD ERNs [8]. These recom-
mendations were generated taking on board the re-
sults achieved by pilot ERNs funded through DG
Sanco or DG Research between 2008 and 2013.
Table 1 Existing networks/projects in the rare disease field supported by EU funding
Group of diseases Networks/Projects
Rare cardiac diseases CHD - Congenital Heart Defects
Rare connective tissue and musculoskeletal diseases PRINTO - paediatric rheumatology international trials organisation
ESDN: European Skeletal Dysplasia Network
Rare hereditary metabolic disorders E-IMD - European registry and network for Intoxication type Metabolic Diseases
EUROGLYCANET CDG: Congenital Disorders of Glycosylation
Rare haematological diseases EPNET – European Porphyria Network
EN-RBD - Rare Bleeding DisordersPaediatric Hodgkin's lymphoma Network
ENERCA - European Network for Rare and Congenital Anaemias
EUHANET - Haemophilia and the rare congenital deficiencies of other coagulation factors
Rare immunological and auto- inflammatory diseases EURO-HISTIO-NET - A reference network for Langerhans cell histiocytosis and associated syndrome
Rare cancers ExPO-r-NeT - European Expert Paediatric Oncology Reference Network for Diagnostics
and Treatment
RARECARENet - Information network on rare cancers
Rare hepatic diseases EUROWILSON: European network on Wilson disease
Rare neurological diseases NEUROPED - European Network of Reference for Rare Paediatric Neurological Diseases
LEUKOTREAT: Leukodystrophies
EUROSCA: European integrated project on spinocerebellar ataxiasE-Pilepsy - Refractory Epilepsy
Rare Neuromuscular diseases Care-NMD - Improving care for Duchenne muscular dystrophy
TREAT-NMD – Neuromuscular network
Rare skin disorders TAG - Together Against Genodermatoses
GENESKIN: European network on rare genetic skin diseases
Rare Pulmonary diseases ECORN CF – Expert Advice on Cystic Fibrosis
PAAIR - Patient Associations and Alpha1 International Registry
ENCE CF-LAM-LTX - European networks of centres of expertise for CF (Cystic Fibrosis), LAM
(Lymphangioleiomyomatosis), and LTX (Lung Transplantation)
EUROCARE CF - Cystic Fibrosis
Rare malformations and developmental anomalies DYSCERNE - Rare Dysmorphic Syndromes
EUROCRAN - Craniofacial anomalies
Rare Kidney diseases EuroCYST initiative - Polycystic Kidney Diseases
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After the publication of the Delegated and Implement-
ing Acts in March 2014 the EJA conducted a mapping
exercise to explore the areas where the previous recom-
mendations needed further attention from the EC Expert
Group on Rare Diseases. That mapping exercise was the
basis for an addendum to the EUCERD recommenda-
tions. Based on the content of the EUCERD Recommen-
dations and the content of the Acts the Addendum to
the Recommendations suggested an illustrative grouping
of RD as a rational approach to RD ERN planning and
to ensure coverage of all RD.
We based our exercise about the grouping of rare dis-
eases on several possible models such as: the alignment of
diseases by clinical area (e.g. Neurology, Neuromuscular,
Psychiatry, Skin, Kidney, etc.), by clinical group (e.g. Gen-
etic Disorders, Metabolic Disorders, Epilepsy, Oncology),
clinical intervention area (e.g. Transplantation, Gene Ther-
apy, Radiotherapy), shared molecular aetiology [11] (e.g.
Underlying disease mechanism or pathway such as fibrosis
or inflammation) or mixed models.
Several successful examples of centres of expertise and
international networks for RD already exist, which may
be viewed as concrete, trusted ‘solutions’ in their field of
expertise and should be approached as case-studies from
which one can derive important lessons for future ERNs.
These tend to be grouped by clinical area or clinical
grouping (e.g. rare anaemias, neuromuscular diseases,
metabolic diseases, rare epilepsies, etc.).
An ERN based on a specific treatment area, such as
for example Gene Therapy, although attractive when
considering clinical trials or therapy development would
inevitably leave numerous rare disease patients without
a “home”. This model would obviously be involved with
different clinical areas and could be regarded as trans-
versal, cutting across numerous medical specialties. Such
a transversal ERN, could not replace ERNs based on
clinical areas or clinical groups and would have to co-
exist alongside these.
ERNs based on shared molecular mechanisms would,
as the former model, be a way of addressing problems
related with clinical trials and drug development. Drugs
that target a molecular pathway that is common to mul-
tiple diseases can, in principle, be used to treat more
than one disease. However, though the concept is inter-
esting in particularly from a research perspective, such
an ERN might prove rather restrictive and too “single
issue”, especially given the multidisciplinarity inherent in
the expectations asked of an ERN.
We therefore compared five examples of disease group-
ing based on clinical areas/groups (the Classical Medical
Ontology; the Orphanet classification; the EURORDIS
preliminary proposal for grouping of rare diseases; the
French filières; and the UK Research Model as established
by the NIHR Translational Research Collaboration on
RD). This comparison enabled us to propose a preliminary
strategy for grouping rare diseases based on the merging
of the common items. The classical medical ontology is
the one used in Internal Medicine textbooks and is usually
organised according to major organs and systems.
Although incomplete for RD, it is widely used for
teaching and is imbedded in the physicians’ way of
thinking. A well-known example is the classification used
in Harrison's Principles of Internal Medicine [12].
The Orphanet classification of rare diseases is struc-
tured around 116 groups of diseases. For the purposes of
creating ERNs, 116 ‘categories’ would be excessive; how-
ever, in terms of thematic grouping Orphanet proposes
31 RD categories [http://www.orphadata.org/cgi-bin/inc/
product3.inc.php]. It is a useful scientific classification;
however, when dealing with ERNs there are some over-
laps and some redundant groups. If, for instance, we
consider the broad group of “Rare genetic diseases”
should sickle cell anaemia be in the scope and expertise
of an ERN for rare genetic diseases or for rare haemato-
logical diseases? Is it practical to have an ERN devoted
to rare intoxications defined by Orphanet as rare intoxi-
cations due to medical products, or should these be in-
corporated in ERNs dealing with, for instance cardiac
disorders for digitalis intoxication or with oncology for
cytostatic intoxication?
The EURORDIS proposal, presented at the workshop
“Rare Disease European Reference Networks (RD ERNs)
and the use of structural funds to support activities for
RD” held in Rome on the 28-29th October 2014 orga-
nises ERNs by clinical area and was based upon research
undertaken by EURORDIS collaborators. This was an
outline document, kindly made accessible to us by
EURORDIS, which drafted groupings to facilitate dis-
cussion with the Council of National Alliances, Council
of European Federations and EURORDIS members
(Table 2). The Second French National Plan for Rare
Diseases mandated the creation of ‘filières de santé mal-
adies rares’. These “French national rare disease health-
care networks” aim to coordinate all the missions and
activities of groups of centres of expertise and related
competence centres in charge of coherent groups of
related rare diseases. At present 23 official networks
were created [http://www.sante.gouv.fr/les-filieres-de-
sante-maladies-rares.html]. The ‘Filières de santé malad-
ies rares’ were adequately based on what was already in
place in the French health system. The main problem
stays when we try to extrapolate these country-specific
pathways to a broader coverage. Also, the ‘themes’ range
from relatively broad (e.g. inborn metabolic diseases or
developmental anomalies and malformations) to disease-
specific (e.g. Amyotrophic Lateral Sclerosis). Given the
lack of therapeutic options for the vast majority of the
6–8000 rare diseases, there is a necessary link between
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research and clinical care provision; therefore, we have
also considered in our analysis the example of how RD
have been grouped by the UK National Institute for
Health Research (NIHR) Translational Research Collab-
oration in Rare Diseases (Table 3).
Conclusion
After analysing these different models we have tried to
merge the common lines having in consideration that
the grouping strategy has to incorporate the need of
having healthcare providers with different roles/expertise
in any network, the fact that a healthcare provider may
take part in different ERNs, the need to have a signifi-
cant collaboration across ERNs as well as within, and
that fluidity and inter-communication between ERNs
should be ingrained in the structure of the network. An-
other important question that was debated was whether
a dedicated ERN for undiagnosed patients would be
feasible or desirable. Here the distinction between truly
undiagnosed patients (those in whom a precise diagnosis
Table 3 UK grouping of rare diseases for research purposes
1. Cancer
2. Cardiovascular
3. Dementia and Neurodegenerative
4. Eye Disease
5. Gastrointestinal
6. Immunological Disorders
7. Metabolism
8. Musculoskeletal Disorders
9. Neuromuscular Disorders
10. Non-Malignant haematology
11. Paediatric (cross-cutting)
12. Renal Disease
13. Respiratory Disease
14. Skin
Legend: example of how RD have been grouped by the UK National Institute
for Health Research (NIHR) - Translational Research Collaboration in
Rare Diseases
Table 2 EURORDIS Proposal for grouping of diseases for ERNs
1. Undiagnosed Conditions RD ERN
2. Immunologically-mediated and Systemic RD ERN
3. Cardio-Vascular Diseases RD ERN
4. Malformations/Medical Genetics/Neuropaediatrics RD ERN
5. Dermatological diseases RD ERN
6. Endocrinal Diseases RD ERN
7. Hepatic gastroenterological and Severe Intestinal Disorders RD ERN
8. Non-Malignant Haematological Diseases RD ERN
9. Hereditary Metabolic Diseases RD ERN
10. Neurological Diseases RD ERN
11. Neuromuscular RD ERN
12. Pulmonary RD ERN
13. Kidney RD ERN
14. Connective Tissue Framework and Specialist Rheumatology
Diseases RD ERN
15. Head & Neck Malformations RD ERN and Sensory Diseases RD ERN
(including rare ophthalmological, congenital and genetic disease)
16. Cancers RD ERN
17. Other Rare Diseases RD ERN
18. Rare Orthopaedic diseases including Complex Spinal Disorders RD ERN
19. Women, neonatal and children RD ERN
Table 4 ORPHANET Classifications
Rare cardiac diseases
Developmental anomalies during embryogenesis
Inborn errors of metabolism
Rare gastroenterological diseases
Rare neurological diseases
Rare abdominal surgical diseases
Rare hepatic diseases
Rare respiratory diseases
Rare urogenital diseases
Rare surgical thoracic diseases
Rare skin diseases
Rare renal diseases
Rare eye diseases
Rare endocrine diseases
Rare haematological diseases
Rare immunological diseases
Rare systemic and rheumatologic diseases
Rare odontological diseases
Rare circulatory system diseases
Rare bone diseases
Rare otorhinolaryngological diseases
Rare infertility disorders
Rare tumours
Rare infectious diseases
Rare intoxications
Rare gynaecological and obstetric diseases
Rare surgical maxillo-facial diseases
Rare allergic disease
Teratological disorders
Rare cardiac malformations
Rare genetic diseases
Legend: Each of these headings represents a separate and more exhaustive
classification. (http://www.orphadata.org/cgi-bin/inc/product3.inc.php)
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is not possible and who may require access to research
programmes for a diagnosis to be achieved, such as is
available via the NIH undiagnosed scheme in the USA)
and the patients who are known to have a particular type
of disease but not yet a precise diagnosis, needs to be
made. As an alternative to a dedicated ‘undiagnosed’ RD
ERN, it is suggested that each ERN should maintain a
‘forum’ for undiagnosed patients suspected to fall within
their area of expertise. Considering what was stated
about how RD ERNs should be structured, the necessity
to encompass all rare disease patients and the merging
of the different models we have studied, we suggest the
constitution of 22 broad groups (Table 5). This list was
posteriorly presented to the Commission Expert group
on Rare Diseases for discussion. Some changes were
suggested and the final grouping (Table 6) was published
as part of the Addendum to the EUCERD recommenda-
tions of January 2013 [8].
As with the previously described models, the pro-
posed model is not perfect. However some of the dif-
ficulties can be overcome as long as the ERNs are
organized as flexible structures with capacity to adjust
to the reality and maintain enough plasticity to share
patients amongst them, in particular the undiagnosed
ones (Fig. 1).
Summary
ERNs must be sufficiently broad and flexible in their
scope to adjust to real life. When establishing ERNs
one should aim to encompass all rare disease patients
including those without a precise diagnosis. To
achieve these goals ERNs should not be considered as
static, nonflexible structures. They should take under
their umbrella those patients that, according to the
state of the art, are considered undiagnosed but
whose clinical manifestations fall in the respective
area of expertise. ERNs should aim to interact with
other ERNs, should share common ontologies and
coding systems, and should have inter-operational IT
technologies. Despite variation in the details of some
of the models, a group of approximately 22–25 clin-
ical disease areas form the core of the different sys-
tems and could be a starting point for a cohesive
European approach.
As with social networks [9] a RD ERN should have a
cooperative structure with decentralized authority. It has
Table 5 Grouping of RD for Future ERNs, based on areas of
overlap in the systems outlined in the text
1. Rare cardiac diseases (with rare cardiac malformations ERN
included or separate)
2. Rare connective tissue and musculoskeletal diseases
3. Rare hereditary metabolic disorders
4. Rare haematological diseases
5. Rare diseases of brain development and rare intellectual disabilities
6. Rare auto-immune and auto inflammatory diseases
7. Rare cancers
8. Rare hepatic diseases
9. Rare gastrointestinal diseases
10. Rare neurological diseases
11. Rare neuromuscular diseases
12. Rare skin disorders
13. Rare pulmonary diseases
14. Rare malformations and developmental anomalies
15. Rare endocrine diseases
16. Rare urogenital diseases
17. Rare renal diseases
18. Rare multi-systemic vascular diseases
19. Rare head and neck diseases
20. Rare gynaecological and obstetric diseases
21. Rare eye diseases
22. Rare bone diseases
Legend: The present list was proposed by the EUCERD Joint Action team and
was subsequently submitted to the Commission Expert group on Rare
Diseases for discussion
Table 6 Grouping rare diseases in thematic networks
Rare immunological and auto-inflammatory diseases
Rare bone diseases
Rare cancers and tumours
Rare cardiac diseases
Rare connective tissue and musculoskeletal diseases
Rare malformations and developmental anomalies and rare intellectual
disabilities
Rare endocrine diseases
Rare eye diseases
Rare gastrointestinal diseases
Rare gynaecological and obstetric diseases
Rare haematological diseases
Rare craniofacial anomalies and ENT (ear, nose and throat) disorders
Rare hepatic diseases
Rare hereditary metabolic disorders
Rare multi-systemic vascular diseases
Rare neurological diseases
Rare neuromuscular diseases
Rare pulmonary diseases
Rare renal diseases
Rare skin disorders
Rare urogenital diseases
Legend: Thematic grouping of networks published in RARE DISEASE
EUROPEAN REFERENCE NETWORKS: ADDENDUM TO EUCERD
RECOMMENDATIONS OF JANUARY 2013
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to build on critical mass and to develop collective
intelligence. Collective intelligence principles, a col-
lective rather than an hierarchical approach to deci-
sion making and development of intellectual content,
are not strange to the healthcare systems and have
been seen as a way of maintaining access to services
that otherwise due to the scarcity of resources the
healthcare system would not be able to offer [13]. For
RDs, ensuring the integration of these core features
poses unique challenges, yet, simultaneously promises
to generate unique added-value. For example, in
terms of ‘collective intelligence’, RD ERNs will support
expert collaboration and communication. It is also
known that in the past a lack of ‘critical mass’ has
hindered RD research and healthcare provision, ERNs
will facilitate this by bringing together patients and
healthcare providers in a sustainable structure with a
clear position within healthcare policy.
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